Company intelligence · NYSE: NVS

Novartis: pipeline and clinical trials

Novartis developed pelacarsen, licensed from Ionis Pharmaceuticals, whose 8,323-patient Lp(a)HORIZON outcomes trial missed its primary endpoint in 2026. Novartis sponsors more than 360 active trials, including two large inclisiran outcomes trials.

Legal name (SEC)NOVARTIS AG
ListingNYSE: NVS
HeadquartersBasel, Switzerland
SEC filingsEDGAR (CIK 1114448)
Focus areasCardiovascular disease, Oncology, Immunology, Neuroscience

Key points

  • Novartis sponsors 362 active trials on ClinicalTrials.gov, including 87 in Phase 3.
  • Pelacarsen's Lp(a)HORIZON trial did not meet its primary endpoint (company-reported September 4, 2026; presented November 7, 2026).
  • Novartis terminated a pelacarsen extension study and withdrew a planned Phase 3 study following the result, according to the registry.
  • Its largest active Phase 3 trials are two inclisiran cardiovascular outcomes studies: VICTORION-2P (17,004 participants) and a primary-prevention trial (14,012 participants).
  • Pelacarsen was discovered by Ionis Pharmaceuticals (Nasdaq: IONS), which co-announced the Lp(a)HORIZON topline result.

Tracked drug profiles

Drugs from this company that Spectral Genomics profiles in depth, with registry data and sourced analysis.

Active clinical trials

ClinicalTrials.gov lists 362 active trials with Novartis as lead sponsor (recruiting, not yet recruiting, active, or enrolling by invitation), retrieved Nov 19, 2026. Counts include only trials whose lead sponsor is registered as "Novartis Pharmaceuticals" or "Novartis".

By phase

Phase 146
Phase 1/225
Phase 267
Phase 2/32
Phase 387
Phase 424
Not applicable111

Most common conditions

  • Breast Cancer (12)
  • Hidradenitis Suppurativa (12)
  • Chronic Spontaneous Urticaria (10)
  • Multiple Sclerosis (9)
  • Relapsing Multiple Sclerosis (8)
  • Immunoglobulin A Nephropathy (6)
  • Atherosclerotic Cardiovascular Disease (6)
  • C3 Glomerulopathy (5)

Conditions as registered by the sponsor; one trial can list several.

Largest active Phase 3 trials

TrialEnrollmentPrimary completion
VICTORION-2P · NCT05030428
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
17,004May 10, 2027
NCT05739383
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
14,012Apr 16, 2029
PINNACLE-MI · NCT07938411
A Study to Assess the Effect of Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial Infarction
10,000Oct 22, 2030
NCT07517263
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
5,700Jan 9, 2030
NATALEE · NCT03701334
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
5,101May 29, 2030
LILAC-TIMI 76 · NCT07739888
Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation
2,500Dec 30, 2030
ALITHIOS · NCT03650114
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
1,882Sep 30, 2028
Adjuvant WIDER · NCT05827081
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
1,466Sep 7, 2029
REMASTER · NCT07225504
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
1,275Dec 3, 2030
PSMAddition · NCT04720157
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
1,144Jan 13, 2025

See this sponsor’s trials on ClinicalTrials.gov

After Lp(a)HORIZON

Pelacarsen was one of the most closely watched cardiovascular drugs in development, and, to our knowledge, the first drug designed specifically to lower Lp(a) to report a cardiovascular outcomes trial. Its neutral result is a significant setback for Novartis and for the field. Several pelacarsen studies remain listed as active in the registry, and their future had not been confirmed in the sources we reviewed.

Cardiovascular pipeline

Novartis's largest active trials are outcomes studies of inclisiran (Leqvio), a PCSK9-targeting siRNA: VICTORION-2P in patients with established cardiovascular disease, and a second trial in high-risk primary prevention. A third large trial, PINNACLE-MI (10,000 participants), is testing pacibekitug after a heart attack. Spectral Genomics does not yet profile these drugs.

What to watch

  • Novartis's decisions on the remaining pelacarsen studies.
  • Results of the inclisiran outcomes trials, which will show whether siRNA-based LDL lowering reduces cardiovascular events.

Partnerships and corporate events

  • Ionis Pharmaceuticals: originator of pelacarsen (formerly AKCEA-APO(a)-LRx), developed by Novartis as TQJ230. Ionis disclosed the Lp(a)HORIZON topline result in an SEC filing. Company-reported

Recent milestones

  1. Dec 12, 2019Lp(a)HORIZON begins. Registry
  2. Sep 4, 2026Lp(a)HORIZON misses its primary endpoint of reducing cardiovascular events. Company-reported
  3. Oct 15, 2026Pelacarsen open-label extension study terminated following the Lp(a)HORIZON outcome. Registry
  4. Nov 7, 2026Full Lp(a)HORIZON results presented at AHA Scientific Sessions: Lp(a) −78% with no reduction in cardiovascular events. Scientific meeting

Sources

  1. SEC EDGAR: Novartis AG filings (CIK 1114448).Regulator
  2. Ionis Pharmaceuticals. Form 8-K, Exhibit 99.1: Lp(a)HORIZON topline results (September 4, 2026).Company-reported
  3. American Heart Association Newsroom. Lp(a) HORIZON trial results (AHA Scientific Sessions 2026).Scientific meeting
  4. ClinicalTrials.gov. VICTORION-2P (NCT05030428).Registry
  5. ClinicalTrials.gov: active trials with this lead sponsorRegistry

This page is for education and research. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported information is labeled. See our disclaimer.